A Study of Tirzepatide (LY3298176) Plus Mibavademab Compared With Tirzepatide Alone in Adult Participants With Obesity

NCT06373146 · Completed

Last updated 2026-05-28

This clinical trial is testing whether adding mibavademab to tirzepatide helps reduce body weight more than tirzepatide alone in adults with obesity.

Status Completed The study has finished.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 392 people

Who can join Ages 18+ · all sexes

Timeline Started 2024-04 · est. completion 2026-04

Where 17 sites · United States

What this study is testing ClinicalTrials.gov NCT06373146 ↗

Description as written by the study sponsor.

The main purpose of this study is to determine if combining tirzepatide with mibavademab will result in more weight loss in adult participants than tirzepatide alone. The study will last about 74 weeks and may include up to 19 visits.

Treatments tested

Tirzepatide also known as LY3298176 Drug

Administered SC
Mibavademab also known as REGN4461 Drug

Administered SC
Tirzepatide-Placebo Drug

Administered SC
Mibavademab-Placebo Drug

Administered SC

Main thing measured	Mean Percent Change from Baseline in Body Weight
Sponsor	Eli Lilly and Company
Conditions studied	Obesity
GLP-1 drugs	tirzepatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06373146 ↗